HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INNOGEN-B

4.080

-0.130-3.09%

Volume:9.61M

Turnover:39.19M

Market Cap:1.86B

PE:-4.43

High:4.230

Open:4.215

Low:4.010

Close:4.210

52wk High:53.000

52wk Low:4.010

Shares:457.00M

HK Float Shares:420.29M

Volume Ratio:0.70

T/O Rate:2.29%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.922

ROE:-36.91%

ROA:-17.30%

PB:1.52

PE(LYR):-4.43

PS:12.15

Loading ...

Overview Company News Filings

INNOGEN-B Shares Surge Over 43% in Morning Trading; Phase III Weight Loss Data for Suba Anticipated by End-2026

INNOGEN-B Shares Hit Record Low as Lock-Up Expiry Nears

Innogen Pharmaceutical Reports No Share Capital Changes in April 2026; Public Float Remains Compliant

Bulletin Express

英诺加医药2025年首度实现收入破1.31509亿元，推进糖尿病及代谢病产品全球布局

Bulletin Express

Guangzhou Innogen Pharma publishes 2025 annual report

Domestic Long-Acting GLP-1 Drug Tops 100 Million Yuan in First-Year Sales but Faces Deepening Losses

INNOGEN-B (02591): 2025 Losses Nearly Double Amid Strategic Transition, Share Price Plummets Over 70%

INNOGEN-B Shares Climb Over 3% in Morning Session as Esupaglutide Alpha Added to Qilu Insurance List

Innogen Pharmaceutical's 2025 Loss Widens

MT Newswires Live

Stock Track | INNOGEN-B Plummets 5.79% Intraday as FY2025 Loss Widens 95.4% on Surging R&D and Commercial Expenses

BRIEF-Guangzhou Innogen Pharmaceutical Posts FY Revenue Rmb131.5 Million

INNOGEN-B Reports Widened Net Loss of 341 Million Yuan for Fiscal Year 2025

Innogen Pharmaceutical posts 2025 maiden revenue of RMB131.51 million; net loss widens on surging R&D and commercial spend

Bulletin Express

Guangzhou Innogen Pharmaceutical - Plans to Enter the Latin America Market

THOMSON REUTERS

Guangzhou Innogen Pharmaceutical - FY Revenue RMB131.5 Mln

THOMSON REUTERS

Guangzhou Innogen launches esupaglutide α for T2D in China, posting CNY 132 million in 2025 revenue

Guangzhou Innogen FY2025 net loss widens 95.4% to RMB341 million as selling and distribution expenses surge to RMB177 million

Innogen Pharmaceutical revises corporate secretarial lineup, obtains continued waiver under HKEX Listing Rules

Bulletin Express

INNOGEN-B (02591) Appoints Mak Po Man as Joint Company Secretary

Guangzhou Innogen appoints Mak Po Man Cherie as joint company secretary, replacing Sze Suet Ling

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02591/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":4.08,"timestamp":1787299688008,"preClose":4.21,"halted":0,"volume":9608610,"delay":0,"changeRate":-0.03087885985748216,"floatShares":420285370,"shares":457000000,"eps":-0.9216253743747356,"marketStatus":"Not Yet Opened","change":-0.13,"latestTime":"08-21 16:08:08","open":4.215,"high":4.23,"low":4.01,"amount":39193170,"amplitude":0.052257,"askPrice":4.08,"askSize":55400,"bidPrice":4.07,"bidSize":8200,"shortable":3,"etf":0,"ttmEps":-0.9647901070986156,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":4.21,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.7016963557043266,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-17.30%","roe":"-36.91%","lyrEps":-0.921625,"volumeRatio":0.7016963557043266,"shares":457000000,"dividePrice":0,"high":4.23,"amplitude":0.052257,"preClose":4.21,"low":4.01,"week52Low":4.01,"pbRate":"1.52","psRate":"12.15","week52High":53,"institutionHeld":0,"latestPrice":4.08,"committee":-0.742138,"eps":-0.9216253743747356,"divideRate":0,"volume":9608610,"delay":0,"ttmEps":-0.9647901070986156,"open":4.215,"prevYearClose":30.64,"prevWeekClose":6.61,"prevMonthClose":7.26,"prevQuarterClose":7.09,"fiveDayClose":6.61,"twentyDayClose":7.59,"sixtyDayClose":11.84,"earningDate":1787587200000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02591","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1775750400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-08-21","current":-4.227909,"percent":1,"low":-137.156472,"twenty":-69.656366,"median":-50.052949,"eighty":-12.083492,"high":-5.675745,"avg":-45.707081,"sd":29.956855,"marketCap":1863822943},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-20","current":-50.419859,"twenty":-79.623791,"median":-62.643943,"eighty":-56.891323,"marketCap":12653895967},{"date":"2026-02-27","current":-50.052949,"twenty":-79.470699,"median":-62.017016,"eighty":-56.651056,"marketCap":12699577902},{"date":"2026-03-06","current":-43.88908,"twenty":-79.397543,"median":-60.902753,"eighty":-56.29247,"marketCap":11045891858},{"date":"2026-03-13","current":-39.965904,"twenty":-79.214462,"median":-60.292057,"eighty":-54.71959,"marketCap":10104843999},{"date":"2026-03-20","current":-39.174717,"twenty":-78.964109,"median":-59.813644,"eighty":-50.865048,"marketCap":9867297938},{"date":"2026-03-27","current":-24.701097,"twenty":-78.775514,"median":-59.491697,"eighty":-50.290678,"marketCap":9547524394},{"date":"2026-04-02","current":-24.535908,"twenty":-78.383597,"median":-58.823921,"eighty":-50.052949,"marketCap":9529251620},{"date":"2026-04-10","current":-24.978414,"twenty":-78.348547,"median":-58.584467,"eighty":-49.631191,"marketCap":9775934068},{"date":"2026-04-17","current":-23.474521,"twenty":-78.227102,"median":-58.112982,"eighty":-48.421657,"marketCap":9191205301},{"date":"2026-04-24","current":-19.658213,"twenty":-78.155492,"median":-57.844151,"eighty":-44.116877,"marketCap":7697406030},{"date":"2026-04-30","current":-16.329046,"twenty":-77.825679,"median":-57.660489,"eighty":-41.074266,"marketCap":6395470886},{"date":"2026-05-08","current":-17.822364,"twenty":-77.322024,"median":-57.626503,"eighty":-40.478309,"marketCap":5778764764},{"date":"2026-05-15","current":-17.368107,"twenty":-77.157551,"median":-57.517602,"eighty":-40.012158,"marketCap":5646287153},{"date":"2026-05-22","current":-17.112125,"twenty":-76.782452,"median":-57.446424,"eighty":-25.37304,"marketCap":5550355090},{"date":"2026-05-29","current":-15.607197,"twenty":-76.252433,"median":-57.23775,"eighty":-24.916387,"marketCap":5079831160},{"date":"2026-06-05","current":-14.014909,"twenty":-75.020932,"median":-57.073515,"eighty":-24.414835,"marketCap":4568193490},{"date":"2026-06-12","current":-11.752443,"twenty":-74.621039,"median":-56.924891,"eighty":-23.900197,"marketCap":3828146144},{"date":"2026-06-18","current":-10.549084,"twenty":-74.404407,"median":-56.73827,"eighty":-23.474521,"marketCap":3444417891},{"date":"2026-06-26","current":-9.60263,"twenty":-74.160764,"median":-56.642046,"eighty":-20.865982,"marketCap":3120076153},{"date":"2026-07-03","current":-11.351574,"twenty":-74.088566,"median":-56.533624,"eighty":-19.581214,"marketCap":3691100339},{"date":"2026-07-10","current":-11.238926,"twenty":-74.037218,"median":-56.208644,"eighty":-19.055481,"marketCap":3649986598},{"date":"2026-07-17","current":-10.540302,"twenty":-73.42668,"median":-55.144116,"eighty":-17.753872,"marketCap":3435281504},{"date":"2026-07-24","current":-10.636027,"twenty":-71.947117,"median":-53.621015,"eighty":-17.028947,"marketCap":3467258858},{"date":"2026-07-31","current":-10.1543,"twenty":-71.465685,"median":-51.153424,"eighty":-16.590446,"marketCap":3316508473},{"date":"2026-08-07","current":-10.609247,"twenty":-70.999854,"median":-50.412223,"eighty":-15.817726,"marketCap":3471827052},{"date":"2026-08-14","current":-9.215586,"twenty":-70.625283,"median":-50.222782,"eighty":-14.020929,"marketCap":3019575896},{"date":"2026-08-21","current":-5.675745,"twenty":-69.656366,"median":-50.052949,"eighty":-12.083492,"marketCap":1863822943}],"updateTime":1787508833990},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1160489079","title":"INNOGEN-B Shares Surge Over 43% in Morning Trading; Phase III Weight Loss Data for Suba Anticipated by End-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1160489079","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160489079?lang=en_us&edition=fundamental","pubTime":"2026-05-11 11:42","pubTimestamp":1778470951,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) rose over 43% in morning trading. As of the time of writing, the stock was up 42.21%, trading at HK$17.99 with a turnover of HK$173 million. According to the company's annual...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4134","BK1161","VXUS","III","BK4588","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129972784","title":"INNOGEN-B Shares Hit Record Low as Lock-Up Expiry Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=1129972784","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129972784?lang=en_us&edition=fundamental","pubTime":"2026-05-07 14:18","pubTimestamp":1778134696,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) fell more than 7% in afternoon trading, hitting a record low of HK$12.33. At the time of writing, the stock was down 6.16% at HK$12.49, with a turnover of HK$11.02 million. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","IPOS","02591","BK1161","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181023653","title":"Innogen Pharmaceutical Reports No Share Capital Changes in April 2026; Public Float Remains Compliant","url":"https://stock-news.laohu8.com/highlight/detail?id=1181023653","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181023653?lang=en_us&edition=fundamental","pubTime":"2026-05-06 11:23","pubTimestamp":1778037794,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) submitted its Monthly Return for Equity Issuer covering the period ended 30 April 2026. Key points are as follows: • Stable...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178804191","title":"英诺加医药2025年首度实现收入破1.31509亿元，推进糖尿病及代谢病产品全球布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1178804191","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178804191?lang=en_us&edition=fundamental","pubTime":"2026-04-28 23:07","pubTimestamp":1777388830,"startTime":"0","endTime":"0","summary":"2025年度，英诺加医药集团有限公司（股份代号：02591，简称“INNOGEN-B”）实现自成立以来的首次营收，报告期内收入约人民币1.31509亿元，主要来自集团核心长效GLP-1受体激动剂Efsugablutide...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英诺加医药2025年首度实现收入破1.31509亿元，推进糖尿病及代谢病产品全球布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630863075","title":"Guangzhou Innogen Pharma publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630863075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630863075?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:53","pubTimestamp":1777387985,"startTime":"0","endTime":"0","summary":"Innogen Pharma annual report for year ended Dec. 31, 2025 flagged a strategic shift toward commercial execution following launch of core GLP-1 product Diabegone  in mainland China in February 2025.Product reached a reimbursement milestone in December 2025 with inclusion in China National Reimbursement Drug List for adult type 2 diabetes, effective Jan. 1, 2026.Group recorded first year of scalable product sales with revenue of RMB 131.51 million, reflecting initial market penetration in China.Pipeline advanced in weight management with Phase III China obesity and overweight study completing enrollment in November 2025, with completion targeted in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Grou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL3jCf9s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100842642","title":"Domestic Long-Acting GLP-1 Drug Tops 100 Million Yuan in First-Year Sales but Faces Deepening Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1100842642","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100842642?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:12","pubTimestamp":1777018368,"startTime":"0","endTime":"0","summary":"INNOGEN-B has become the first domestic company to commercialize a long-acting GLP-1 drug following the approval of its Esupaglutide α injection in 2025. One year later, the company released its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK4144","BK4590","GLP","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127480276","title":"INNOGEN-B (02591): 2025 Losses Nearly Double Amid Strategic Transition, Share Price Plummets Over 70%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127480276","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127480276?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:18","pubTimestamp":1775477936,"startTime":"0","endTime":"0","summary":"The year 2025 marked a pivotal period of strategic transformation for INNOGEN-B (02591), as the company shifted from a pure research and development focus to a dual approach integrating R&D with...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147586009","title":"INNOGEN-B Shares Climb Over 3% in Morning Session as Esupaglutide Alpha Added to Qilu Insurance List","url":"https://stock-news.laohu8.com/highlight/detail?id=1147586009","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147586009?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:38","pubTimestamp":1775093921,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) rose more than 3% during morning trading. At the time of writing, the stock was up 2.94% to HK$22.22, with a turnover of HK$1.966 million. On April 1, INNOGEN announced via its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","VXUS","BK4585","BK4588","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621321340","title":"Innogen Pharmaceutical's 2025 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2621321340","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621321340?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:11","pubTimestamp":1774321897,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  booked 341.4 million yuan in attributable loss for 2025, widening from a loss of 174.7 million yuan in  2024, according to a Hong Kong bourse filing Monday.Loss per share was 0.79 yuan, compared with 0.42 yuan in the prior year.Revenue for the year was 131.5 million yuan. The company did not generate any revenue in 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188306372","title":"Stock Track | INNOGEN-B Plummets 5.79% Intraday as FY2025 Loss Widens 95.4% on Surging R&D and Commercial Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=1188306372","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188306372?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:42","pubTimestamp":1774316538,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) shares plummeted 5.79% during Tuesday's intraday trading session, following the release of the company's first post-IPO annual results for the fiscal year 2025.The pharmaceutical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621070763","title":"BRIEF-Guangzhou Innogen Pharmaceutical Posts FY Revenue Rmb131.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621070763","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621070763?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:18","pubTimestamp":1774279127,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Posts FY Revenue Rmb131.5 MillionMarch 23  - Guangzhou Innogen Pharmaceutical 2591.HK:FY REVENUE RMB131.5 MILLIONFY LOSS ATTRIBUTABLE RMB341.4 MILLIONPLANS TO ENTER THE LATIN AMERICA MARKETFurther company coverage: 2591.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103158318","title":"INNOGEN-B Reports Widened Net Loss of 341 Million Yuan for Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1103158318","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103158318?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:16","pubTimestamp":1774278975,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced its financial results for the year ended December 31, 2025. The group reported revenue of approximately 131.5 million yuan, primarily generated from the sales of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190961010","title":"Innogen Pharmaceutical posts 2025 maiden revenue of RMB131.51 million; net loss widens on surging R&D and commercial spend","url":"https://stock-news.laohu8.com/highlight/detail?id=1190961010","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190961010?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:02","pubTimestamp":1774278135,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group (Innogen-B) released its first post-IPO annual results, highlighting the transition from pure R&D to simultaneous development and commercialisation. Revenue and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621870210","title":"Guangzhou Innogen Pharmaceutical - Plans to Enter the Latin America Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2621870210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621870210?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277747,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621021447","title":"Guangzhou Innogen Pharmaceutical - FY Revenue RMB131.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621021447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621021447?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702129","title":"Guangzhou Innogen launches esupaglutide α for T2D in China, posting CNY 132 million in 2025 revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702129","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702129?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277731,"startTime":"0","endTime":"0","summary":"Innogen reported the China approval and commercial launch of its core product, yisupaglutide α, for adult type 2 diabetes, marking a shift toward a combined R&D-and-commercial model.National reimbursement listing for the adult type 2 diabetes indication is scheduled to take effect on Jan. 1, 2026, which may expand patient access and support broader hospital uptake.The company said it is pursuing lifecycle expansion into weight management and MASH, targeting additional revenue streams beyond the initial diabetes market.Overseas filings were submitted in Hong Kong and selected markets in Southeast Asia and Latin America, positioning the product for potential regional commercialization partnerships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL4htKm7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702126","title":"Guangzhou Innogen FY2025 net loss widens 95.4% to RMB341 million as selling and distribution expenses surge to RMB177 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702126","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702126?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277727,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen FY2025 net loss widens 95.4% to RMB341 million as selling and distribution expenses surge to RMB177 million. Innogen published an annual results announcement for the year ended Dec. 31, 2025.Revenue was RMB131.5 million, while gross profit was RMB117.1 million.Loss for the year widened to RMB341.4 million, and basic and diluted loss per share was RMB0.79.Research and development expenses rose 100.7% to RMB205.8 million, driven by higher pre-clinical and clinical trial and process optimization fees and higher raw materials costs tied to Efsubaglutide Alfa.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via II","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL6kt3KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180017707","title":"Innogen Pharmaceutical revises corporate secretarial lineup, obtains continued waiver under HKEX Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1180017707","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180017707?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:23","pubTimestamp":1774268588,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced several governance adjustments effective 23 March 2026. Joint Company Secretary Sze Suet Ling will resign from her...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112376071","title":"INNOGEN-B (02591) Appoints Mak Po Man as Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=1112376071","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112376071?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:10","pubTimestamp":1774267820,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that Ms. Shi Xueling has resigned from her positions as (i) Joint Company Secretary of the Company, (ii) the Company's Authorized Representative for accepting service of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703329","title":"Guangzhou Innogen appoints Mak Po Man Cherie as joint company secretary, replacing Sze Suet Ling","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703329","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703329?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:05","pubTimestamp":1774267514,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen said Suet Ling Sze resigned as joint company secretary, agent for service of process, and authorized representative, effective March 23, 2026.Mak is vice president of SWCS Corporate Services Group  and has over 20 years of experience in audit, accounting, corporate finance, compliance, and corporate secretarial work.Dongyan Yang will continue as the other joint company secretary and has served as the group’s legal director since April 2021.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 23, 2026, and is solely respon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL97VtGk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":92,"code":"91000000","status":"200"}]}}